$31.23
1.67% day before yesterday
Nasdaq, Aug 01, 10:00 pm CET
ISIN
US4158581094
Symbol
HROW

Harrow Health, Inc. Stock price

$31.23
+0.46 1.50% 1M
+1.40 4.69% 6M
-2.32 6.92% YTD
+6.68 27.21% 1Y
+24.48 362.67% 3Y
+25.51 445.98% 5Y
+23.39 298.34% 10Y
+22.58 261.10% 20Y
Nasdaq, Closing price Fri, Aug 01 2025
-0.53 1.67%
ISIN
US4158581094
Symbol
HROW
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$1.3b
Net debt
$154.1m
Cash
$66.7m
Shares outstanding
35.7m
Valuation (TTM | estimate)
P/E
negative | 139.1
P/S
5.4 | 3.9
EV/Sales
6.1 | 4.5
EV/FCF
negative
P/B
20.3
Financial Health
Equity Ratio
17.9%
Return on Equity
-25.1%
ROCE
2.6%
ROIC
-
Debt/Equity
3.9
Financials (TTM | estimate)
Revenue
$212.9m | $291.8m
EBITDA
$20.8m | $85.5m
EBIT
$4.5m | $42.1m
Net Income
$-21.7m | $8.0m
Free Cash Flow
$-36.6m
Growth (TTM | estimate)
Revenue
53.5% | 46.2%
EBITDA
319.0% | 262.1%
EBIT
161.6% | 363.5%
Net Income
30.7% | 145.8%
Free Cash Flow
-156.9%
Margin (TTM | estimate)
Gross
74.5%
EBITDA
9.8% | 29.3%
EBIT
2.1%
Net
-10.2% | 2.7%
Free Cash Flow
-17.2%
More
EPS
$-0.6
FCF per Share
$-1.0
Short interest
14.3%
Employees
382
Rev per Employee
$520.0k
Show more

Is Harrow Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,029 stocks worldwide.

Harrow Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Harrow Health, Inc. forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Harrow Health, Inc. forecast:

Buy
92%
Hold
8%

Financial data from Harrow Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
213 213
53% 53%
100%
- Direct Costs 54 54
29% 29%
25%
159 159
64% 64%
75%
- Selling and Administrative Expenses 141 141
47% 47%
66%
- Research and Development Expense 13 13
62% 62%
6%
21 21
319% 319%
10%
- Depreciation and Amortization 16 16
32% 32%
8%
EBIT (Operating Income) EBIT 4.52 4.52
162% 162%
2%
Net Profit -22 -22
31% 31%
-10%

In millions USD.

Don't miss a Thing! We will send you all news about Harrow Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harrow Health, Inc. Stock News

Neutral
GlobeNewsWire
5 days ago
NASHVILLE, Tenn., July 29, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the second quarter ended June 30, 2025, on Monday, August 11, 2025, after the market close.
Neutral
Business Wire
17 days ago
NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter “Samsung Bioepis”) to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar...
Neutral
Business Wire
17 days ago
INCHEON, Korea--(BUSINESS WIRE)-- #biosimilars--Samsung Bioepis Co., Ltd. (“Samsung Bioepis”) announced today that the company has entered into a license, development and commercialization agreement (DCA) with Harrow (Nasdaq: HROW), for Samsung Bioepis' ophthalmology portfolio — BYOOVIZ® (ranibizumab-nuna), a biosimilar referencing LUCENTISi (ranibizumab) and OPUVIZ™ (aflibercept-yszy), a biosi...
More Harrow Health, Inc. News

Company Profile

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Head office United States
CEO Mark Baum
Employees 382
Founded 2006
Website www.harrow.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today